Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Biohaven Ltd. (NYSE:BHVN) have earned an average rating of “Moderate Buy” from the seventeen research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $22.2667.

A number of equities research analysts have weighed in on BHVN shares. Morgan Stanley decreased their price objective on Biohaven from $21.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday. Citigroup lifted their target price on shares of Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. HC Wainwright cut their target price on shares of Biohaven from $11.00 to $10.00 and set a “neutral” rating for the company in a research note on Wednesday, March 4th. Wall Street Zen cut shares of Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $15.00 target price on shares of Biohaven in a research note on Tuesday, March 3rd.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of BHVN. AQR Capital Management LLC raised its stake in shares of Biohaven by 49.4% in the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after acquiring an additional 37,981 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Biohaven by 32.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after acquiring an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Biohaven by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after acquiring an additional 41,040 shares during the last quarter. Intech Investment Management LLC raised its stake in shares of Biohaven by 80.3% in the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after acquiring an additional 27,433 shares during the last quarter. Finally, Quantbot Technologies LP raised its stake in shares of Biohaven by 1,097.8% in the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock valued at $125,000 after acquiring an additional 8,102 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Stock Down 0.2%

NYSE BHVN opened at $8.74 on Monday. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. The stock’s 50 day moving average is $9.57 and its two-hundred day moving average is $10.60. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -1.54 and a beta of 1.32. Biohaven has a 1-year low of $7.48 and a 1-year high of $18.57.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Equities analysts forecast that Biohaven will post -2.97 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.